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ABSTRACT 
Osmotic drug delivery uses the osmotic pressure level for controlled delivery of drugs by using osmogens. Osmotic systems for  controlled drug-
delivery applications are well established, both in human pharmaceuticals and in veterinary medicine. The process of osmosis is that can control 
the drug delivery system. Osmotic pressure created from external environment into the dosage form regulates the delivery of drug from osmotic 
device. Osmotic pumps are promising systems for controlled drug delivery. The systems are used for oral administration and 
implantation. Osmotic pumps consist of an inner core containing drug and coated with a semi permeable membrane. 
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Drug delivery System:1-3 
Drug delivery is refers to the approaches, formulations, 
technologies, and systems for transporting the compound in 
the body as needed to safely achieve its desired therapeutic 
effect. It may be involve scientific site-targeting within the 
body or it might involve facilitating 
systemic pharmacokinetics in any case, it is typically 
concerned with both quantity and duration of drug presence. 
Drug delivery is often approached via a drug's chemical 
formulation, but it may also involve medical devices or drug-
device combination products. 
Drug delivery of the technologies modifies drug release 
profile absorption, distribution and elimination for the 
benefit of improving product efficacy and safety as well as 
patient convenience and compliance. Drug release is from 
diffusion, degradation, swelling, and affinity based 
mechanisms. 
Novel drug delivery system: 
 In the novel drug delivery systems (NDDS), there are 
various novel carriers which have advantage over 
conventional dosage forms. Conventional dosage forms show 
high dose and low availability, in-stability, first pass effect, 
plasma drug level fluctuations and rapid release of the drug. 
 Novel drug delivery system is one of the important tool of 
developed drug markets in pharmaceutical industry. Novel 
drug delivery system can minimize the problems by 
enhancing efficacy, safety, patient compliance and product 
shelf life.4 
Osmotic drug delivery System: 
Osmotic drug delivery system has come a long way since 
Australian physiologists Rose and Nelson developed an 
implantable pump in 1955. Osmotic drug delivery system 
used to the osmotic pressure for controlled delivery of drugs 
by using osmogens (for up to 10 – 16 hrs). Osmotic systems 
for controlled drug-delivery applications are well 
established, both in human pharmaceuticals and in 
veterinary medicine.5 oral drug delivery systems are known 
to provide the immediate release of drug, in which one 
cannot control the release of the drug and cannot maintain 
effective concentration at the target site for longer time.6few 
one compartment and two-compartment osmotic systems 
have been reviewed previously.7-10 
Osmotically controlled drug delivery system delivery the 
drug in a large extent and the delivery nature is independent 
of the physiological factors of the gastrointestinal tract and 
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these systems can be utilized for systemic as well as targeted 
delivery of drugs. Osmotically controlled oral drug delivery 
systems utilize osmotic pressure for controlled delivery of 
active agents.11 
 Osmotic Pump Controlled Release Preparation is a novel 
drug delivery system with permanently drug delivery rate as 
characteristic and controlled with the osmotic pressure 
difference between inside and outside of the semi permeable 
membrane as drug delivery power.12 
Osmosis can be defined as the spontaneous movement of a 
solvent from a solution of lower solute concentration to a 
solution of higher solute concentration through an ideal semi 
permeable membrane, which is permeable only to the 
solvent but should not permeable to the solute. The  
pressure applied to the higher concentration side to inhibit 
solvent flow is called the osmotic pressure13. 
OSMOSIS 
Process of movement of the solvent from the lower 
concentration of solution to the higher concentration of the 
solution through the semi permeable membrane. Osmosis is 
the process of control the drug delivery system. Osmotic 
pressure created due to imbibing of fluid from external 
environment into the dosage form regulates the delivery of 
drug from osmotic device. 
Rate of drug delivery from osmotic pump is directly 
proportional to the osmotic pressure developed due to 
imbibing of fluids by osmogen. Osmotic pressure is a 
colligative properties of   a solution in which the magnitude 
of osmotic pressure of the solution is independent on the 
number of discrete entities of solute present in the solution. 
Hence the release rate of drugs from osmotic distribute 
devices is dependent on the solubility and molecular weight 
and activity coefficient of the solute.14 
Principle of Osmosis: 
The first report of an osmotic effect dates to Abbenollet 
(1748). But Pfeffer obtained the first quantitative 
measurement in 1877. In the experiment a membrane 
permeable to water but impermeable to sugar is used to 
separate a sugar solution from pure water. A flow of water 
then takes place into the sugar solution that cannot be stop 
until a pressure π is applied to the sugar solution. Pfeffer 
showed that this pressure, the osmotic pressure π of the 
sugar solution is directly proportional to the solution 
concentration and the complete temperature. Within few 
years, Vant Hoff had shown the analogy between these 
results and ideal gas laws by the expression  
                                                        π = Ф c r t  
Where; 
 Ф = osmotic coefficient of the solution, 
 c = molar concentration of sugar in the solution, 
 r= gas constant,  
 t = absolute temperature.  
Osmotic pressure for concentrated solution of soluble 
solutes commonly used in controlled release formulation are 
extremely high ranging from 30 atm for sodium phosphate 
up to 500 atm  for a lactose-fructose mixture, as their 
osmotic pressure can produce high water flow across semi 
permeable membrane. The osmotic water flow through a 
membrane is given by the equation  
                                           Dv/dt = A Q Δ π/L  
Where 
 dv\dt =water flow across the membrane of area 
 A= thickness L, and the permeability  
Q in cm2, Δ π is the osmotic pressure difference between the 
two solutions on either side of the membrane.  
This equation is strictly for completely perm selective 
membrane that is membrane permeable to water but 
completely impermeable to osmotic agent.15 
Instrumentation 
Types of Osmotic Pumps; 
Osmotic pump; 
Osmotic pumps are most good systems for controlled drug 
delivery. These systems are used to oral 
administration. Osmotic pumps consist of an inner core 
containing drug coated with a semi permeable membrane. 
Rose-Nelson Pump; 
Rose and Nelson, the Australian scientists, were initiators of 
osmotic drug delivery. In 1955, they developed an 
implantable pump for the delivery of drugs to the sheep and 
cattle gut. 
 
Figure 1: Rose Nelson Pump. 
A semi-permeable membrane separate the salt from water 
chamber. The movement of water from the water chamber 
towards salt chamber is affcet by difference in osmotic 
pressure across the membrane. The volume of salt chamber 
increases due to water flow, which distends the latex 
diaphragm dividing the salt and drug chambers eventually, 
the drug is pumped out of the device. 
The kinetics of pumping from Rose Nelson pump is given by 
the following equation:  
dMt/ dt= (dV/ dt).C, 
where dMt/dt is the drug release rate, dV/dt is the volume 
flow of water into the salt chamber, and C represents the 
concentration of drug in the drug chamber. 
The major problem connect with Rose-Nelson pumps was 
that the osmotic action began whenever water came in 
contact with the semi permeable membrane. This needed 
pumps to be stored empty and water to be loaded prior to 
use. 
dMt/dt=AӨ∆π C/l 
where, A is the area of semi permeable membrane, Δπ is the 
osmotic pressure gradient, θ is the permeability of semi-
permeable membrane, and l is the thickness of semi-
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permeable membrane. These basic equations are relevant to 
the osmotically driven controlled drug delivery devices. The 
saturated salt solution created a high osmotic pressure 
compare to that pressure required for pumping the 
suspension of active agent. Therefore, the rate of water 
entering into the salt chamber remains constant as long as 
sufficient solid salt is present in die salt chamber to maintain 
a saturated solution and thereby a constant osmotic pressure 
driving force is generated. Major problem associate with 
Rose-Nelson pumps was that the osmotic action began 
whenever water came in contact with the semi-permeable 
membrane. This pumps to be stored empty and water to be 
loaded prior to use16. 
Higuchi-Leeper Osmotic Pump; 
 
Figure 2: Higuchi-Leeper osmotic pump 
This variation allows the device to be prepare loaded with 
drug and can be stored for long prior to use. Higuchi-Leeper 
pumps contain a rigid housing and a semi-permeable 
membrane supported on a perforated frame; a salt chamber 
containing a fluid solution with an excess of solid salt is 
usually present in this type of pump. Upon 
administration/implantation, surrounding biological fluid 
penetrates into the device through porous and semi-
permeable membrane and dissolves the MgSO4, creating 
osmotic pressure inside the device that pushes movable 
separator toward the drug chamber to remove drug outside 
the device. It is widely employed for the veterinary use. This 
type of pump is insert in body of an animal for delivery of 
antibiotics or growth hormones to animals.17 
Pulsatile delivery could be achieved by using Higuch- 
Leeper pump; 
The Pulsatile release of drug is achieved by drilling the 
orifice in elastic material that elastic under the osmotic 
pressure.  
 
Figure 3: Pulsatile release osmotic pump 
Pulse release of drug is obtained after attained a certain 
critical pressure, which causes the orifice to open. The 
pressure then reduces to cause orifice closing and the cycle 
repeats to provide drug delivery in a pulsatile fashion. The 
orifice should be small enough to be substantially closed 
when the threshold level of osmotic pressure is not 
present.18 
Higuchi-Theeuwes Osmotic Pump; 
In this device, the rigid housing consisted of a semi-
permeable membrane. This membrane is strong enough to 
with stand the pumping pressure developed inside the 
device due to of water. The drug is loaded in the device only 
prior to its application, which extends advantage for storage 
of the device for longer duration. The release of the drug 
from the device is governed by the salt used in the salt 
chamber and the permeability characteristics of the outer 
membrane.19 
 
Figure 4: Higuchi Theeuwes Pump. 
Elementary Osmotic Pump (EOP); 
The Rose-Nelson pump was further simplified in the form of 
elementary osmotic pump which made osmotic delivery as a 
major method of achieve controlled drug release20-21. 
Elementary osmotic pump shown was invented by 
essentially contains an active agent having a suitable osmotic 
pressure; it is fabricated as a tablet coated with semi 
permeable membrane, usually cellulose acetate.22-23 
 
Figure 5: The elementary osmotic pump. 
The pump initially releases the drug at a rate given by the 
following equation; 
dMt/dt=(dV/dt).cs 
where  dV/dt depicts the water flow into the tablet and Cs is 
the solubility of the agent inside the tablet. 
Push-Pull Osmotic Pump (PPOP); 
Push-pull osmotic pump is delivered both poorly water 
soluble and highly water soluble drugs at a constant rate. 
This system resembles a standard bilayer coated tablet 
contains drug in a formulation of polymeric, osmotic agent, 
and other tablet excipients. This polymeric osmotic agent has 
the capacity to form a suspension of drug in situ. When this 
tablet later imbibes water, the other layer contains osmotic 
and colouring agents, polymer and tablet excipients. These 
layers are formed and bonded together by tablet 
Venkateswarlu  et al                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):611-616 
ISSN: 2250-1177                                                                                  [614]                                                                                 CODEN (USA): JDDTAO 
 
compression to form a single bilayer core. The tablet core is 
then coated with semi-permeable membrane. After the 
coating has been applied, a small hole is drilled through the 
membrane by a laser or mechanical drill on the drug layer 
side of the tablet.24-25 
 
Figure 6: The push-pull osmotic pump (PPOP). 
Controlled Porosity Osmotic Pump (CPOP); 
Figure 6 represents the controlled porosity osmotic pump 
(CPOP). It is an osmotic tablet wherein the delivery orifices 
(holes) are formed in situ through leaching of water soluble 
pore-forming agents incorporated in semi-permeable 
membrane (SPM) (e.g., urea, nicotinamide, sorbitol, etc.). 
Drug release rate from CPOP depends on various factors like 
coating thickness, solubility of drug in tablet core, level of 
leachable pore-forming agent(s) and the osmotic pressure 
difference across the membrane26-27 
There are several obvious advantages inherent to the CPOP 
system. The stomach irritation problems are considerably 
reduced, as drug is released from the whole of the device 
surface rather from a single hole.27 
 
Figure 9: controlled porosity osmotic pump 
BASIC COMPONENTS OF OSMOTIC SYSTEMS 
Drug; 
Which have short biological half-life and which is used for 
prolonged treatment are ideal character for osmotic systems. 
Various drug candidates such as Diltiazem HCl, 
Carbamazepine, Metoprolol, Oxprenolol, etc are formulated 
as osmotic delivery. 
Semi-permeable membrane; 
An important part of the osmotic drug delivery system is the 
semi-permeable membrane housing. Therefore, the 
polymeric membrane selection is key to the osmotic delivery 
formulation. The membrane should possess certain 
characteristics, such as impermeability to the passage of 
drug and other ingredients present in the compartments. 
The membrane should be inert and maintain its dimensional 
integrity to provide a constant osmotic driving force during 
drug delivery.28 
Any polymer that is permeable to water but impermeable to 
solute can be used as a coating material in osmotic devices. 
e.g. Cellulose esters like cellulose acetate, cellulose acetate 
butyrate, cellulose triacetate and ethyl cellulose and 
Eudragits.29 
Flux regulators; 
Delivery systems can be designed to regulate the 
permeability of the fluid by incorporating fluxregulating 
agents in the layer. Hydrophilic substances such as 
polyethethylene glycols (300 to 6000 Da), polyhydric 
alcohols, polyalkylene glycols, and the like improve the flux, 
whereas hydrophobic materials such as phthalates 
substituted with an alkyl or alkoxy (e.g., diethyl phthalate or 
dimethoxy ethylphthalate) tend to decrease the flux. 
Insoluble salts or insoluble oxides, which are substantially 
water-impermeable materials, also can be used for this 
purpose.30 
Coating solvent; 
Solvents suitable for making polymeric solution that is used 
for manufacturing the wall of the osmotic device include 
inert inorganic and organic solvents that do not adversely 
harm the core, wall and other materials. The typical solvents 
include methylene chloride, acetone, methanol, ethanol, 
isopropyl alcohol, butyl alcohol, ethyl acetate, cyclohexane, 
carbon tetrachloride, water etc. The mixtures of solvents 
such as acetone-methanol (80:20), acetone-ethanol (80:20), 
acetone-water (90:10), methylene chloride-methanol 
(79:21), methylene chloride-methanol-water (75:22:3) etc. 
can be used.31 
Wicking agent; 
A wicking agent is of either swellable or non-swellable 
nature. They are characterized by having the ability to 
undergo physiosorption with water. Physiosorption is a form 
of absorption in which the solvent molecules can loosely 
adhere to surface of the wicking agent via Van der waals 
interactions between the surface of the wicking agent and 
the absorbed molecule. The function of the wicking agent is 
to carry water to surfaces inside the core of the tablet there 
by creating channels or a network of increased surface area. 
Materials, which suitably for act as wicking agents include 
colloidal silicon dioxide, kaolin, titanium dioxide, alumina, 
niacinamide, sodium lauryl sulphate (SLS), low in weight 
poly (vinyl pyrolidone) PVP , m-pyrol, bentonite, magnesium 
aluminium silicate, polyester and polyethylene. SLS, colloidal 
silica and PVP are non swellable wicking agents.32 
Pore forming agent; 
The pore-forming agents cause the formation of micro 
porous membrane. The micro porous wall may be formed in 
situ by a pore-former by its leaching during the operation of 
the system. Thepore-formers can be inorganic or organic and 
solid or liquid in nature. For example, alkaline metal salts 
such as sodium chloride, sodium bromide, potassium 
chloride, potassium sulphate, potassium phosphate etc., 
alkaline earth metals such as calcium chloride and calcium 
nitrate, carbohydrates such as sucrose, glucose, fructose, 
mannose, lactose, sorbitol, and mannitol and, diols and 
polyols such as poly hydric alcohols, polyethylene glycols 
and polyvinyl pyrrolidone can be used as pore forming 
agents.33 
Plasticizers;34 
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Different types and amount of plasticizers used in coating 
membrane also have a significant importance in the 
formulation of osmotic systems. They can change visco-
elastic behaviour of polymers and these changes may affect 
the permeability of the polymeric films. Some of the 
plasticizers used are as below. 
 Polyethylene glycols 
 Ethylene glycol monoacetate 
 Diacetate- for low permeability 
 Tri ethyl citrate 
 Diethyl tartarate or Diacetin- for more permeable films 
Osmotic agent;35-37 
These are also known as osmogents and are used to create 
osmotic pressure inside the system. When the solubility of 
drug is low then the drug will show zero order release but at 
a slow rate. To enhance the release rate osmotic agent is 
added in the formulation. Osmotic agent creates a very high 
osmotic pressure gradient inside the system and increases 
release rate of drug. 
Some of the commercially used osmotic agents; 
Sodium chloride, Fructose, Sucrose, Potassium chloride, 
Xylitol, Sorbitol, Citric acid, Dextrose, 
Manitole and Lactose. 
Some Mixture Used As an Osmotic Agent; 
 Dextrose +Fructose 
 Lactose +Fructose36 
 Sucrose+ Fructose 
 Lactose +Dextrose 
 Mannitol +Fructose 
 Mannitol +Dextrose 
 Dextrose +Sucrose 
 Mannitol +Sucrose 
APPLICATION:38 
Osmotically controlled oral drug delivery system utilizes 
osmotic pressure for controlled delivery of active agent. 
Alza corporation of USA was first to develop an oral osmotic 
pump,even today they are leaders in this field with a 
technology named OROSTM. 
Osmotic pumps have made tremendous progress and the 
available products based on this technology and number of 
patents granted in the last few years makes its presence felt 
in the market. 
Apart from drug delivery osmotic pumps can be used as 
experimental tools to determine important pharmacokinetic 
parameters of new existing drugs. 
Elementary osmotic pumps are suitable for delivery of drugs 
having moderate water solubility. 
Push-pull osmotic pumps can be used for delivery of drugs 
having extremes of water solubility 
ADVANTAGES39-43 
 The release rate of osmotic systems is highly predictable 
and can be programmed by modulating the release 
control parameters. 
 The delivery rate of zero-order is achievable with 
osmotic systems. 
 In the osmotic pump tablet frequency of dosing is 
reduced due to drug being released over a longer period 
of time unlike conventional tablets 
 The delivery rate of zero-order is achievable with 
osmotic systems. 
 Delivery may be delayed or pulsed, if desired. 
 Higher release rates are possible with osmotic systems 
compared with conventional diffusion-controlled drug 
delivery systems. 
 For oral osmotic systems, drug release is independent of 
gastric pH and hydrodynamic conditions. 
 The release from osmotic systems is minimally affected 
by the presence of food in gastrointestinal tract. 
 A high degree of in vivo- in vitro correlation (IVIVC) is 
obtained in osmotic systems. 
DISADVANTAGES 
Release rate: The drug release rate can be altered by food 
and gastric transit time; as a result differences may arise in 
the release rate between doses. 
 Can not crush or chew products: Osmotic pump tablet 
should not be crushed or chewed as it can lead to loss of the 
‘slow release’ characteristics as well as toxicity.44 
MARKETED PRODUCT45 
 Elementary Osmotic Pump 
Brand Name API 
Efidac 24 Chlorpheniramine 
Acutrim Phenylpropanolamine 
Sudafed 24 Pseudoephedrine 
Volmax Albuterol 
Minipress XL Prazocine 
 
Push-Pull Osmotic Systems 
Ditropan XL Oxybutynin chloride 
Procardia XL Nifedipine 
Glucotrol Glipizide 
Covera HS Verapamil HCl 
DynaCirc CR Isradipine 
Invega Paliperidone 
 
Implantable Osmotic Systems 




 Osmotic drug delivery system are known to provide 
prolonged and controlled release of the drugs their by 
maintaining the effective concentration at the target site for 
longer duration.The osmotic delivery of drugs based on 
above review of the system.osmotic drugs delivery system is 
observed to provide a better delivery system of drugs 
intended for better therapeutic efficacy.   
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